Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.
Saved in:
| Title: | Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. |
|---|---|
| Authors: | van Dorp J; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands., Pipinikas C; Inivata Ltd., Babraham Research Park, Cambridge, UK., Suelmann BBM; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Mehra N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., van Dijk N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Marsico G; Inivata Ltd., Babraham Research Park, Cambridge, UK., van Montfoort ML; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hackinger S; Inivata Ltd., Babraham Research Park, Cambridge, UK., Braaf LM; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Amarante T; Inivata Ltd., Babraham Research Park, Cambridge, UK., van Steenis C; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands., McLay K; Inivata Ltd., Babraham Research Park, Cambridge, UK., Daletzakis A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Kamp MW; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., Hendricksen K; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., de Feijter JM; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boellaard TN; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Meijer RP; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urological Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Heijden AG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Rosenfeld N; Inivata Ltd., Babraham Research Park, Cambridge, UK.; Cancer Research UK Cambridge Institute, Cambridge, UK.; Cancer Research UK Major Centre Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK., van Rhijn BWG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany., Jones G; Inivata Ltd., Babraham Research Park, Cambridge, UK. greg.jones@inivata.com., van der Heijden MS; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands. ms.vd.heijden@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ms.vd.heijden@nki.nl. |
| Source: | Nature medicine [Nat Med] 2024 Jan; Vol. 30 (1), pp. 304. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37460757 AccessLevel: 2 PubTypeId: unknown PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22van+Dorp+J%22">van Dorp J</searchLink>; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Pipinikas+C%22">Pipinikas C</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Suelmann+BBM%22">Suelmann BBM</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mehra+N%22">Mehra N</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Dijk+N%22">van Dijk N</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Marsico+G%22">Marsico G</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22van+Montfoort+ML%22">van Montfoort ML</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hackinger+S%22">Hackinger S</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Braaf+LM%22">Braaf LM</searchLink>; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Amarante+T%22">Amarante T</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22van+Steenis+C%22">van Steenis C</searchLink>; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22McLay+K%22">McLay K</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Daletzakis+A%22">Daletzakis A</searchLink>; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+den+Broek+D%22">van den Broek D</searchLink>; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+de+Kamp+MW%22">van de Kamp MW</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Hendricksen+K%22">Hendricksen K</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Feijter+JM%22">de Feijter JM</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Boellaard+TN%22">Boellaard TN</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Meijer+RP%22">Meijer RP</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urological Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Heijden+AG%22">van der Heijden AG</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Rosenfeld+N%22">Rosenfeld N</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK.; Cancer Research UK Cambridge Institute, Cambridge, UK.; Cancer Research UK Major Centre Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22van+Rhijn+BWG%22">van Rhijn BWG</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.<br /><searchLink fieldCode="AU" term="%22Jones+G%22">Jones G</searchLink>; Inivata Ltd., Babraham Research Park, Cambridge, UK. greg.jones@inivata.com.<br /><searchLink fieldCode="AU" term="%22van+der+Heijden+MS%22">van der Heijden MS</searchLink>; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands. ms.vd.heijden@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ms.vd.heijden@nki.nl. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2024 Jan; Vol. 30 (1), pp. 304. – Name: TypePub Label: Publication Type Group: TypPub Data: Published Erratum – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE; PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37460757 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1038/s41591-023-02500-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 304 Titles: – TitleFull: Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: van Dorp J – PersonEntity: Name: NameFull: Pipinikas C – PersonEntity: Name: NameFull: Suelmann BBM – PersonEntity: Name: NameFull: Mehra N – PersonEntity: Name: NameFull: van Dijk N – PersonEntity: Name: NameFull: Marsico G – PersonEntity: Name: NameFull: van Montfoort ML – PersonEntity: Name: NameFull: Hackinger S – PersonEntity: Name: NameFull: Braaf LM – PersonEntity: Name: NameFull: Amarante T – PersonEntity: Name: NameFull: van Steenis C – PersonEntity: Name: NameFull: McLay K – PersonEntity: Name: NameFull: Daletzakis A – PersonEntity: Name: NameFull: van den Broek D – PersonEntity: Name: NameFull: van de Kamp MW – PersonEntity: Name: NameFull: Hendricksen K – PersonEntity: Name: NameFull: de Feijter JM – PersonEntity: Name: NameFull: Boellaard TN – PersonEntity: Name: NameFull: Meijer RP – PersonEntity: Name: NameFull: van der Heijden AG – PersonEntity: Name: NameFull: Rosenfeld N – PersonEntity: Name: NameFull: van Rhijn BWG – PersonEntity: Name: NameFull: Jones G – PersonEntity: Name: NameFull: van der Heijden MS IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2024 Jan Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1546-170X Numbering: – Type: volume Value: 30 – Type: issue Value: 1 Titles: – TitleFull: Nature medicine Type: main |
| ResultId | 1 |